What is the Origin of SURMOUNT-1 Trial?

The trial is part of the broader SURMOUNT clinical program, initiated by the pharmaceutical developer to rigorously test the compound tirzepatide, which acts on two key incretin hormone receptors, GIP and GLP-1, to understand its comprehensive metabolic effects.

What is the Mechanism of SURMOUNT-1 Trial?

The study's mechanism of action centers on tirzepatide's dual agonism, which mimics the action of the endogenous incretin hormones GIP and GLP-1. This combined signaling enhances glucose-dependent insulin secretion, improves insulin sensitivity, and critically, acts on central nervous system pathways to reduce appetite and food intake, resulting in substantial, sustained body weight reduction that goes beyond typical hormonal weight-loss effects.

SURMOUNT-1 Trial ∞ Area

SURMOUNT-1 Trial

Meaning

The SURMOUNT-1 Trial is a pivotal, multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical investigation designed to evaluate the efficacy and safety of the dual GIP and GLP-1 receptor agonist, tirzepatide, for chronic weight management in adults with obesity or overweight and related comorbidities, but notably without diabetes. This landmark study provides critical data on the hormonal regulation of body weight and metabolic health, informing future therapeutic standards in endocrinology and obesity medicine.